We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

BioXell and Lay Line Announce License Agreement

BioXell and Lay Line Announce License Agreement

BioXell and Lay Line Announce License Agreement

BioXell and Lay Line Announce License Agreement

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioXell and Lay Line Announce License Agreement "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioXell S.p.A. and Lay Line Genomics S.p.A. have announced an exclusive, worldwide license agreement for the development of MNAC13, a humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor (NGF), a key mediator of pain.

According to the agreement, BioXell will take MNAC13 through development and potential commercialisation, in exchange for an undisclosed upfront payment, milestones and royalties to LLG.

MNAC13 belongs to a class of pain therapeutics that might represent a promising alternative to opioids such as morphine. Among its potential advantages are an improved safety profile and higher specificity which allow for improved efficacy and enhanced compliance.
"I am very proud of our team for moving MNAC13 to this advanced stage. We are extremely pleased that BioXell shares our excitement about MNAC13 and will be bringing its resources and expertise to the development of a novel potential pain therapeutic," said Antonino Cattaneo, President and CSO of LLG.

"This agreement further validates the power of LLG's antibody technologies and will allow us to concentrate our efforts on the development of LLG's Alzheimer's disease therapeutic and diagnostics programmes."
"This exciting programme perfectly fits into our pipeline and provides a near-term clinical development opportunity," said Francesco Sinigaglia, CEO of BioXell.

"NGF and its high affinity receptor TrkA are validated targets for pain, and we intend to explore the therapeutic potential of MNAC13 in specific conditions for which current therapeutic options are largely unsatisfactory."

"In addition to oncological pain and chronic inflammatory conditions such as osteoarthritis, we believe that MNAC13 may find an extremely promising field of application in Chronic Pelvic Pain Syndromes (CPPS), such as interstitial cystitis and chronic non-bacterial prostatitis."